ReviewRevista de neurologia2022
Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert.
Review in Revista de neurologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Effects of a gait training program with the FisiorBMC complementary medicine and therapies · 2026Trial
- Three-dimensional Motion Capture Discriminates Extremely Mild Cerebellar Ataxia from Parkinsonism in the Upper Limbs.Cerebellum (London, England) · 2026Article
- Systematic review of unveiling the potential of AI using machine learning and deep learning methods in neurodegenerative diseases.PeerJ. Computer science · 2026Review
- A Real-World Study on Unstable Parkinson's Disease: Levodopa Dosage Management and the Role of Nonmotor Symptoms.Movement disorders clinical practice · 2025Article
- Pharmacogenetics in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Effects of Square Stepping Exercise on Physical, Cognitive and Psychosocial Fitness in People with Parkinson's Disease.The Psychiatric quarterly · 2025Article
- Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study.Biomedicines · 2025Article
- Predictive Value of Brain Volumetry in the Response to Subthalamotomy Using High-Intensity Focused Ultrasound Treatment in Patients With Parkinson's Disease.Parkinson's disease · 2025Article
- Understanding Parkinson's disease: current trends and its multifaceted complications.Frontiers in aging neuroscience · 2025Review
- Long-Term Real-World Experience with Safinamide in Patients with Parkinson's Disease.Brain sciences · 2024Article
- The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.Actas espanolas de psiquiatria · 2024Article
- Neuroprotective Effects Exerted by a Combination of Selected Lactic Acid Bacteria in a Mouse Parkinsonism Model under Levodopa-Benserazide Treatment.Neurochemical research · 2024Article
- Association of Serum Extracellular Vesicle miRNAs with Cognitive Functioning and Quality of Life in Parkinson's Disease.Biomolecules · 2024Article
- Effects of Intracerebral Aminophylline Dosing on Catalepsy and Gait in an Animal Model of Parkinson's Disease.International journal of molecular sciences · 2024Article
- Exploring barriers and educational needs in implementing dual-task training for Parkinson's disease: insights from professionals.Frontiers in medicine · 2024Article
- Mapping knowledge domain of acupuncture for Parkinson's disease: a bibliometric and visual analysis.Frontiers in aging neuroscience · 2024Article
- Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.Revista de neurologia · 2023Article
- Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review.Brain sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParkinson's disease (PD) is a neurodegenerative multisystemic disorder that affects approximately 1% of the population over 55 years old, with the mean age of onset at 60 years old, and the prevalence of the disease constantly growing. DEVELOPMENT: PD is a progressive disease characterized by motor and non-motor symptoms that compromise patients' daily activities. It has a variable profile of onset and clinical evolution. Although currently available treatments have failed to clinically demonstrate neuroprotective properties, most motor symptoms are acceptably managed with dopaminergic medication. More than 50 years after launching levodopa, it remains the most effective treatment of motor symptoms in PD, able to provide sustained benefit throughout the entire course of the disease. Nevertheless, after two to three years of treatment, certain fluctuations start to appear in motor and non-motor responses to different doses of levodopa. Early identification and treatment of these fluctuations have a strong positive impact on the quality of life of the patient. Frequently accompanied by involuntary movements, proper control of fluctuations requires periodical adjustments of the medication and expert supplementation with dopaminergic and non-dopaminergic adjuvants.
conclusionsThe main purpose of this work is to offer a practical, updated guideline for neurologists regarding the use of dopaminergic agents from the initial stages of PD. Special emphasis is placed on the critical period after the end of the 'honeymoon' phase when variations in the symptomatology presented by each patient appear, forcing re-adjustment of the medication to fit their individual needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.